This segment focuses on the development, manufacturing, and commercialization of molecular diagnostic kits for oncology. Amoy Diagnostics employs real-time PCR, NGS, and FISH technologies to detect gene mutations and biomarkers relevant to various cancers. R&D efforts are directed towards expanding the range of detectable biomarkers and improving the sensitivity and specificity of diagnostic assays. These diagnostics aid in treatment selection, monitoring disease progression, and predicting patient outcomes. The company collaborates with pharmaceutical companies to develop companion diagnostics for targeted therapies, enhancing personalized cancer treatment strategies. By providing accurate and timely diagnostic information, Amoy Diagnostics aims to improve patient outcomes and contribute to the advancement of precision oncology.

Amoy Diagnostics actively engages in the development of companion diagnostics (CDx) in collaboration with pharmaceutical partners. This segment focuses on creating diagnostic assays that identify patients most likely to benefit from specific targeted therapies. The company leverages its expertise in PCR and NGS technologies to develop CDx for various oncology drugs. These assays are crucial for patient stratification in clinical trials and for guiding treatment decisions in clinical practice. Amoy Diagnostics' collaborations with pharmaceutical companies like AstraZeneca, Merck KGaA, and Boehringer Ingelheim demonstrate its commitment to advancing personalized medicine. By providing reliable and clinically validated CDx, Amoy Diagnostics contributes to the efficient and effective use of targeted therapies, ultimately improving patient outcomes in oncology.